RCELNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as AVHHL
AVITA Medical, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$13.14+0.10 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $404.05M
- P/E (TTM)
- –
- Dividend yield
- –
AVITA Medical, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPK | $10.60M | $9.40M | $8.50M | $8.30M | $9.30M | $9.50M | $9.30M | $7.60M | $613.00K | – | – | – | 48.8% | +14.0% |
| PermeaDerm | – | – | $0 | $0 | $0 | $6.00M | – | – | – | – | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $20.85M | $18.57M | $17.10M | $16.03M | $17.90M | $17.76M | $18.00M | $19.05M | $14.58M | $10.53M | $12.98M | $12.96M | 96.1% | +16.5% |
| Japan | $387.00K | $439.00K | $422.00K | $605.00K | $427.00K | $634.00K | $194.00K | $388.00K | $389.00K | $461.00K | $1.06M | $581.00K | 1.8% | -9.4% |
| Australia | $194.00K | $40.00K | $40.00K | $80.00K | $40.00K | $40.00K | $180.00K | $54.00K | $61.00K | $17.00K | $66.00K | $61.00K | 0.9% | +385.0% |
| European Union | $182.00K | $0 | $0 | $0 | $0 | $49.00K | $0 | $0 | $103.00K | $51.00K | – | – | 0.8% | – |
| United Kingdom | $93.00K | $202.00K | $51.00K | $345.00K | $55.00K | $35.00K | $37.00K | $56.00K | $60.00K | $43.00K | $37.00K | $42.00K | 0.4% | +69.1% |
From the segment and revenue-disaggregation notes of AVITA Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.